Clinical trials
Alzheimer s Disease clinical trials
Below are recruiting alzheimer s disease clinical trials, each written for real people, not researchers. We’re tracking 600 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07598370RecruitingPhase 1
Testing LY3439539 for early-stage Alzheimer's disease
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
Irvine, CaliforniaAges 50–85 - NCT07571161RecruitingPhase 3
Donanemab for early Alzheimer's disease in Chinese participants
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
BeijingAges 55–80 - NCT06732128Recruiting
Nature virtual reality for depression in Alzheimer's disease
This trial tests whether a virtual reality nature experience can help improve mood in people with early-to-moderate Alzheimer's disease. Participants will use a VR headset and a few apps at home, with a caregiver present, over several sessions.
Toronto, OntarioAges 50 years+ - NCT07545473Recruiting
Eye Imaging to Detect Brain Disease Markers
This study uses a special camera to photograph the back of your eye in detail. Researchers believe changes in the eye may reflect brain diseases like Alzheimer's or Parkinson's, and this imaging could help detect these conditions earlier.
Melbourne, VictoriaAges 30 years+ - NCT07543094Enrolling by invitation
Brain Stimulation for Early Alzheimer's Memory and Thinking
This study tests whether a special type of brain stimulation called temporal interference stimulation can improve memory and thinking skills in people with early-stage Alzheimer's disease. The treatment uses electrical stimulation to target specific brain areas without surgery.
Shanghai, Shanghai MunicipalityAges 50–75 - NCT05801380Recruiting
Tracking how well a medicine works in Alzheimer’s patients
This study looks at how effective a treatment is in people newly diagnosed with mild to moderate Alzheimer’s disease. It also involves health and medication history checks and likely stool (fecal) sample collection to monitor effects.
Manila, National Capital RegionAges 65 years+ - NCT06535308RecruitingPhase 1
Testing a new Alzheimer's drug for moderate disease
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Seoul, Jongno-guAges 19–45 - NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT06837272Recruiting
Gut health and brain health in Alzheimer's disease
This study looks at how the bacteria in your gut might be connected to memory and thinking problems in Alzheimer's disease. It may help us understand if changes in the gut can affect brain health.
Jining, ShandongAges 60–80 - NCT06841848Recruiting
Eye camera test for early Alzheimer's
This study is testing a new eye camera to see if it can help find early signs of Alzheimer's disease. It is for people aged 55 and older who either have mild to moderate Alzheimer's or do not have Alzheimer's.
Rome, ItalyAges 55 years+ - NCT05413655RecruitingPhase 2
Oral drug for mild Alzheimer’s disease symptoms
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
TaipeiAges 50–80 - NCT07328451RecruitingPhase 1
Study of DNL628 for people with early Alzheimer's disease
This trial tests an experimental drug, DNL628, to see if it is safe and how it affects people with early Alzheimer's disease. It may help slow the disease by targeting a specific process in the brain.
's-HertogenboschAges 18–75 - NCT07323927RecruitingEarly Phase 1
Testing galcanezumab for Alzheimer's disease
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
BeijingAges 50–90 - NCT06874231Recruiting
Brain connectivity marker for Alzheimer's disease
This study uses brain scans to find a marker for Alzheimer's disease. It is looking for people with normal memory, mild memory problems, or mild Alzheimer's, and who can undergo a spinal tap and MRI.
Stockholm, SolnaAges 40–85 - NCT07294885Recruiting
Lymphatic surgery for Alzheimer's disease
This study tests a surgical procedure to connect lymph vessels in the neck to veins, which may help clear waste from the brain in people with mild cognitive impairment or mild to moderate Alzheimer's disease. It is for patients who have not improved after at least 3 months of standard care.
ShenyangAges 50–80 - NCT06883019Recruiting
Lecanemab for early onset inherited Alzheimer's
This trial tests a medication called lecanemab for people with early onset familial Alzheimer's disease. It aims to see if the drug can help slow cognitive decline in those with confirmed signs of Alzheimer's in their brain.
Beijing, ChinaAges 18–65 - NCT07213349RecruitingPhase 2
Daridorexant for Alzheimer's prevention
This study tests whether daridorexant, a medication that helps improve sleep, can prevent Alzheimer's disease. If you have mild memory concerns but not dementia, this trial may help find out if better sleep can protect your brain.
Montreal, QuebecAges 50–90 - NCT07208344RecruitingEarly Phase 1
Umbilical cord blood infusion for Alzheimer's disease
This early-phase study tests whether infusing donated umbilical cord blood (a source of young immune cells) can help slow Alzheimer's disease. It is for people aged 50–75 with mild to moderate Alzheimer's who have a caregiver and are otherwise generally healthy.
Hefei, AnhuiAges 50–75 - NCT06936124Recruiting
Deep brain stimulation for Alzheimer's disease
This trial tests whether deep brain stimulation of a specific brain area can help people with Alzheimer's disease. It aims to see if this treatment can improve symptoms and quality of life.
Toronto, OntarioAges 60 years+ - NCT07153848Recruiting
Lecanemab treatment for early Alzheimer's disease
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
Hangzhou, ZhejiangAges 45–85 - NCT07142954RecruitingPhase 3
Alzheimer's research study for healthy people
This study is looking at healthy people with no memory concerns to better understand early signs of Alzheimer's disease. You would provide samples and do thinking tests, but you won't take any experimental medicines.
Houston, TexasAges 55–75 - NCT07127510Recruiting
Brain NAD in Alzheimer's disease study
This study tests whether a natural substance called NAD can improve brain health in people with early Alzheimer's. You may be eligible if you have a firm Alzheimer's diagnosis, are between 65 and 80, and can walk and talk without help.
Boca Raton, FloridaAges 65–80 - NCT06385106Recruiting
Brain stimulation for memory loss in Alzheimer's
This study tests if repetitive transcranial magnetic stimulation (a non-invasive brain stimulation technique) can help improve memory and thinking in people with Alzheimer's disease. It may be an option if you are between 55 and 80, right-handed, and have a confirmed diagnosis of Alzheimer's.
Hangzhou, ZhejiangAges 55–80 - NCT07094438RecruitingPhase 1
Brain stimulation and neck surgery for severe Alzheimer's
This early-stage trial tests combining deep brain stimulation (a device that sends electrical pulses to the brain) with a neck surgery that aims to improve brain fluid drainage. It's for people with severe Alzheimer's who can still walk and do not have other major health issues.
BeijingAges 40–80
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for alzheimer s disease?
- Yes. Clin2 currently lists 600 recruiting alzheimer s disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a alzheimer s disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a alzheimer s disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.